Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03207256 · ClinicalTrials.gov registry record · Phase 2
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
A Phase 2 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03207256 is a Phase 2 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 51 participants.
The verdict
NCT03207256, a Phase 2 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Interventions
- DRUG TGR-1202
- DRUG TGR-1202 + Ublituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-08-09 |
| Est. Completion | 2022-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03207256
The ClinicalTrials.gov registry entry for NCT03207256 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TGR-1202 is the first listed.
NCT03207256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03207256 about?
NCT03207256 is a clinical study titled "Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials". This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
What is the current status of trial NCT03207256?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-08-09. Estimated completion is 2022-06-24.
What interventions are being tested in trial NCT03207256?
The interventions under investigation include: TGR-1202 (DRUG), TGR-1202 + Ublituximab (DRUG).
Who is sponsoring clinical trial NCT03207256?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.